BRD2 and cancer: As an imprinted oncogenic NAT, FOXD2-AS1 can upregulate the expression of telomerase reverse transcriptase (TERT), the catalytic subunit of telomerase, by sponging miR-7-5p, maintaining and facilitating cancer stem cell phenotypes in thyroid cancer [113].